This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Novus Biologicals
other brands :
IMGENEX
product type :
antibody
product name :
GM-CSF Antibody
catalog :
33090002
quantity :
0.1 mg
price :
349 USD
clonality :
polyclonal
host :
domestic rabbit
conjugate :
nonconjugated
reactivity :
human
citations: 2
Reference |
---|
product information
brand :
Novus
master code :
33090002
SKU :
33090002-0.1mg
product name :
GM-CSF Antibody
description :
The GM-CSF Antibody from Novus is a rabbit polyclonal antibody to GM-CSF. This antibody reacts with human. The GM-CSF Antibody has been validated for the following applications: ELISA.
target :
GM-CSF
category :
Primary Antibodies
unit size :
0.1 mg
buffer :
20 mM Potassium Phosphate (pH 7.0), 0.15 M NaCl
clonality :
Polyclonal
conjugate :
Unconjugated
host :
Rabbit
immunogen :
This antibody is specific for the entire range of the target protein.
isotype :
IgG
purity :
Immunogen affinity purified
species :
Human
gene symbol :
CSF2
catalog number base :
33090002
accessionNumbers :
P04141
applications :
ELISA
USD :
349 USD
alt names :
colony stimulating factor 2 (granulocyte-macrophage), Colony-stimulating factor, CSF, GM-CSF, GMCSFgranulocyte-macrophage colony-stimulating factor, granulocyte-macrophage colony stimulating factor, MGC131935, MGC138897, molgramostin, sargramostim
storage :
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
company information

Novus Biologicals
8100 Southpark Way, A-8
Littleton, CO 80120
Littleton, CO 80120
novus@novusbio.com
https://www.novusbio.com3037301950
headquarters: USA
Novus Biologicals licenses, manufactures, and markets antibodies to over 20,000 unique targets to support a wide array of research areas. Novus is built on honesty, collaboration and strong relationships and continues to provide quality tools that accelerate research. Every product is backed by our 100% guarantee.
questions and comments